Acalabrutinib with bendamustine and rituximab for treating previously untreated mantle cell lymphoma

Acalabrutinib in combination with bendamustine and rituximab is in clinical development for the
first line treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of nonHodgkin lymphoma. It affects the B-cells (a type of white blood cells) and develops in the lymph
nodes. The abnormal B-cells start to collect in the lymph nodes or body organs, where they can
form tumours and begin to cause problems within the lymphatic system or the organ where they
are growing. Current first-line treatment of MCL involves treatment options that can be high
intensity and unsuitable for the elderly, thus There is a medical need for novel strategies to
improve disease control in patients with MCL.